591-600 of 2937 results
Arbitration Insights July 2022
In this inaugural Arbitration Insights, we look at the amended ICSID rules, recent decisions of the NSW Supreme Court and the Federal Court, and more. ...
New Aim Pty Ltd v Leung: assisting expert witnesses – how much is too much?
In New Aim Pty Ltd v Leung the Federal Court of Australia rejected an expert report and oral evidence from a purportedly independent expert witness, on the basis that the solicitors who retained the expert had written her report. The case is a timely reminder of best (and worst) practices in the engagement of independent expert witnesses and the importance of preserving an expert's independence. ...
Doubling of FIRB application fees
On 22 July 2022, the Government released changes to the FIRB application fee regime, in the form of the Foreign Acquisitions and Takeovers Fees Imposition Amendment (Fee Doubling) Regulations 2022 (Cth). The Amending Regulations provide for a doubling of FIRB application fees from 29 July 2022, we outline and comment on the fee increases. ...
In Touch: Energy industry granted interim authorisation and other developments
The latest in competition and consumer law. ...
Employment and Safety: Key employment changes from 1 July 2022 and other developments
The latest issues, decisions and proposed changes impacting business and workplace risk ...
Overview of Australia's foreign investment approval (FIRB) regime
Significant changes to Australia's foreign investment approval (FIRB) regime came into effect last year. This guide provides up-to-date information you need to know about how the new FIRB regime operates. ...
More detail on the ESB's proposed capacity mechanism
With so much recent commentary on the perks and pitfalls of a capacity mechanism, this Insight takes a step back and unpacks what we know about the proposal and what it will look like for both generators and retailers in the future. ...
The mRNA rush
There is great potential for mRNA technology to revolutionise future vaccines, and treatment of various conditions such as rare genetic disorders, other infectious diseases and even cancer. The enthusiasm for the technology – or the 'mRNA rush' – is reflected by a spike in patent filings over the past five years, and the growing patent portfolios of key mRNA pioneers and market players. ...
Failure to pay patent renewal fee? Advanta can take advantage of extension of time provision
Advanta Seeds Pty Ltd (Advanta), a broadacre seed company that owns thousands of patents relating to agricultural chemicals, seeds and seed technologies, applied for review of a decision by the Commissioner of Patents refusing its application under s 223 Patents Act 1990 (Cth) (Patents Act) for an e ...